MeiraGTx Holdings: Gaining Regulatory Focus

I used to cover MeiraGTx (NASDAQ: MGTX ) a few years ago, but haven’t looked at it since 2022. MGTX develops genetic therapies for ocular diseases, Parkinson’s Disease and xerostomia. Lead asset is AAV-AQP1 targeting Xerostomia in a pivotal phase 2About the TPT ServiceThanks for reading. At the Total Pharma Tracker, we offer the following:-Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where you can enter any ticker and get extensive curated rese ...